74 filings
8-K
FSTX
F-star Therapeutics Inc
9 Mar 23
Completion of Acquisition or Disposition of Assets
8:27am
8-K
FSTX
F-star Therapeutics Inc
7 Mar 23
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
9:08am
8-K
FSTX
F-star Therapeutics Inc
6 Mar 23
Entry into a Material Definitive Agreement
9:31am
8-K
FSTX
F-star Therapeutics Inc
23 Feb 23
Entry into a Material Definitive Agreement
8:45am
8-K
FSTX
F-star Therapeutics Inc
9 Feb 23
Entry into a Material Definitive Agreement
9:01am
8-K
y6qvq3ez
1 Feb 23
Entry into a Material Definitive Agreement
8:44am
8-K
cewvvctazd8cze5c roq
30 Dec 22
Entry into a Material Definitive Agreement
8:37am
8-K
0vt29b586m 588n
29 Dec 22
Other Events
9:02am
8-K
73b5rdl6
21 Dec 22
Entry into a Material Definitive Agreement
6:08am
8-K
5losm53hv1h
19 Dec 22
Entry into a Material Definitive Agreement
11:57am
8-K
d4vvtu2 2l65lqjjel
21 Nov 22
Entry into a Material Definitive Agreement
6:36am
8-K
4uv21lq
1 Nov 22
Other Events
8:58am
8-K
vz9 7nwkj
11 Aug 22
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
9:20am
8-K
30wdh
23 Jun 22
Invox Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
9:25am
8-K
nk7js
16 Jun 22
Submission of Matters to a Vote of Security Holders
5:18pm
8-K
zci 9ory8orua5d6erz
10 May 22
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:22am
8-K
psl5vcjsq8eg877ac8d
14 Mar 22
F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
8:09am
8-K
ndga2z4u69
6 Jan 22
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
8:16am
8-K
52a 5wszb8j7kkf
12 Nov 21
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
8:34am
8-K
9dzr78y
10 Nov 21
F-star Therapeutics Reports Third Quarter 2021 Financial Results
8:30am